Breyer Capital — 2021 Investments
3 investments dated 2021 · listed companies and verified rows first · show all
Earli develops a biotechnology platform that uses genetic constructs to detect cancer and produce therapeutic proteins by reprogramming cancer cells.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesSouth San Francisco, US
Dr. Sam Gambhir(Founder)Cyriac Roeding(Co-founder)inDr. David Suhy(Co-founder & Chief Scientific Officer)
BoardJustin Kao(Director)inJorge Conde(Director)in
Co-investorsAndreessen HorowitzHan River PartnersMenlo VenturesDFJMBX Capital
OM1 develops AI-powered analytics and data infrastructure for healthcare organizations to measure patient outcomes, predict health trajectories, and accelerate medical research using real-world clinical data.
AI & Machine LearningData & InfrastructureHealthtechMedical DevicesBoston, US
Richard Gliklich, MD(Founder)Richard E. Gliklich(Executive Officer, Director)
BoardRory O'Driscoll(Director)Larry Bohn(Director)David Barrett(Director)Gary Gottlieb(Director)
Co-investors7wire VenturesCorewell Health VenturesM33 GrowthScale Venture Partners
Postera uses artificial intelligence and computational chemistry to accelerate drug discovery for pharmaceutical companies.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesBoston, US
Aaron Morris(Founder)inAlpha Lee(Founder)inMatthew Robinson(Founder)in
Co-investorsHOF CapitalLifeforce CapitalMetaplanetY CombinatorACE & Company
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.